You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2025

Bulk Pharmaceutical API Sources for methylene blue


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for methylene blue

Vendor Vendor Homepage Vendor Sku API Url
ChemBridge ⤷  Get Started Free 5104371 ⤷  Get Started Free
Vitas-M Laboratory ⤷  Get Started Free STK018918 ⤷  Get Started Free
TCI (Tokyo Chemical Industry) ⤷  Get Started Free A0574 ⤷  Get Started Free
TCI (Tokyo Chemical Industry) ⤷  Get Started Free A5105 ⤷  Get Started Free
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for Methylene Blue

Last updated: July 29, 2025

Introduction

Methylene Blue (MB), a synthetic aromatic chemical compound, has a longstanding history in medicine, primarily utilized as a dye, an antiseptic, and a treatment for certain medical conditions such as methemoglobinemia. As a critical pharmaceutical ingredient, sourcing high-quality Methylene Blue API is essential for pharmaceutical manufacturing, research, and clinical applications. The global supply chain for MB API involves a range of manufacturers, primarily based in Asia, Europe, and North America, with varying degrees of regulatory approval and manufacturing standards.

This comprehensive overview delineates the key suppliers, geopolitical landscapes, manufacturing standards, and logistical considerations for sourcing Methylene Blue API in bulk. This information aims to assist pharmaceutical companies, research institutions, and procurement professionals in navigating the complex global market effectively.

Global Methylene Blue API Suppliers

Asia

India

India remains a dominant player in the API manufacturing sector, owing to its extensive chemical industry infrastructure and cost advantages. Several Indian firms manufacture Methylene Blue API, often catering to both domestic and international markets.

  • Sun Pharmaceuticals: One of India's largest pharmaceutical conglomerates, Sun Pharmaceuticals, supplies Methylene Blue API, primarily for domestic use and export. The company adheres to cGMP standards, ensuring quality compliance.

  • Zida Chem: Specializing in dyes and intermediates, Zida Chem offers Methylene Blue API with ISO 9001 certification, supporting bulk procurement for both pharmaceutical and research applications.

  • LGC Standards India: While primarily a supplier of research chemicals, LGC provides Methylene Blue APIs compliant with pharmacopoeial standards for analytical and laboratory purposes.

China

China's API manufacturing sector is robust, with several companies producing Methylene Blue API at large scales. Chinese suppliers often cater to both pharmaceutical and industrial markets.

  • Northwest Pharma: Known for its dye and pharmaceutical intermediates, this company supplies Methylene Blue API with certifications aligning with international GMP standards.

  • Hubei Wukela Pharmaceutical Co.: An emerging API manufacturer with a focus on dye intermediates and APIs, including Methylene Blue, meeting ISO and pharmacopoeial standards.

  • Shanghai Shengda Biotechnologies: Supplies Methylene Blue API, primarily targeting research and clinical trial markets, with compliance to global quality specifications.

Europe

European manufacturers tend to focus on high-quality standards, adhering strictly to GMP and pharmacopoeial standards, suitable for clinical and advanced pharmaceutical applications.

  • Sartorius Stedim Biotech: Although primarily a biotech equipment producer, Sartorius distributes high-purity Methylene Blue for research and pharmaceutical use from certified suppliers.

  • Sigma-Aldrich (now part of Merck): Offers pharmaceutical-grade Methylene Blue API, compliant with USP, EP, and JP standards, supporting bulk orders for research, diagnostics, and pharmaceuticals.

  • Biosynth Carbosynth: Supplies high-purity Methylene Blue with strict adherence to cGMP standards, catering to clinical applications.

North America

American firms emphasize compliance with regulatory standards such as FDA, USP, and cGMP, primarily focusing on pharmaceutical-grade API supply.

  • Prime Formulations Inc.: Provides Methylene Blue API in bulk quantities, emphasizing quality and regulatory compliance for clinical and pharmaceutical manufacturing.

  • Illumina Inc.: Although mainly focused on diagnostics, they distribute high-quality Methylene Blue APIs suitable for laboratory and research applications.

Other notable suppliers

  • EPCOT International: Based in the UK, supplies pharmaceutical-grade Methylene Blue with certifications supporting export and clinical use.

  • BioReagents Inc.: US-based, offers high-purity dyes including Methylene Blue for therapeutics and research purposes.

Manufacturing Standards and Regulatory Compliance

The quality and regulatory standards vary among suppliers, significantly impacting drug safety and efficacy.

  • Good Manufacturing Practice (GMP): Essential for APIs intended for human pharmaceutical use. Suppliers such as Sigma-Aldrich, Biosynth Carbosynth, and Prime Formulations meet GMP standards for clinical applications.

  • Pharmacopoeial Standards: Many suppliers produce Methylene Blue API conforming to USP, EP, JP, or BP monographs, ensuring purity, stability, and consistent quality.

  • ISO Certifications: Suppliers often hold ISO 9001, 14001, and 13485 certifications, indicating adherence to quality management and environmental standards.

Quality Considerations

  • Purity Levels: Pharmaceutical-grade Methylene Blue typically features >98% purity, with low residual solvents and impurities vetted via HPLC and UV spectroscopy.

  • Packaging and Storage: Suppliers provide API in sealed, light-protected containers to prevent photodegradation, with specifications supporting stability during transportation and storage.

Logistical Factors in Sourcing

  • Lead Times: Suppliers with existing inventory can fulfill bulk orders within 2-4 weeks, while custom synthesis and quality testing may extend this period.

  • Pricing Dynamics: Cost varies depending on purity level, quantity, supplier location, and logistical considerations. Competitive bidding among Indian and Chinese manufacturers often results in lower per-unit costs.

  • Import Regulations: Procurement must consider import controls, customs tariffs, and licensing requirements, especially when sourcing from non-Western regions.

  • Supply Chain Risks: Dependence on specific regions may introduce supply disruptions; diversifying suppliers mitigates risks.

Emerging Trends in API Sourcing

  • Supply Chain Localization: Recent disruptions have prompted pharmaceutical companies to consider domestic or nearby developers compliant with regional regulations.

  • Quality Assurance Advancements: Increased reliance on certificated vendors to ensure API conformity amid stricter regulatory scrutiny.

  • Sustainability and Ethical Sourcing: Growing demand for environmentally sustainable manufacturing practices influence supplier selection, emphasizing eco-friendly production methods.

Conclusion

The bulk sourcing of Methylene Blue API involves a diversified ecosystem comprising Indian, Chinese, European, and North American manufacturers. Ensuring compliance with GMP and pharmacopoeial standards remains paramount, highly influencing supplier selection based on intended application and regulatory jurisdiction. Strategic procurement balancing cost, quality, regulatory compliance, and supply chain resilience enhances operational stability and product safety.


Key Takeaways

  • Indian and Chinese suppliers offer cost-effective bulk Methylene Blue API, with increasing focus on quality standards aligning with GMP and pharmacopoeial norms.

  • European and North American manufacturers prioritize high purity, regulatory compliance, and traceability, suitable for clinical and pharmaceutical applications.

  • Due diligence—including certification verification, testing, and understanding import regulations—is necessary for quality assurance.

  • Diversification of suppliers mitigates risks linked to geopolitical and logistic disruptions.

  • Staying abreast of emerging trends in sustainable manufacturing and supply chain localization can benefit procurement strategies.


FAQs

1. What are the key quality standards to look for when sourcing Methylene Blue API?
Suppliers should provide APIs conforming to USP, EP, or JP monographs, with purity levels exceeding 98%, validated via HPLC or UV spectroscopy, and certified under GMP where intended for pharmaceutical use.

2. Is it possible to source Methylene Blue API for research purposes outside of GMP constraints?
Yes, research-grade Methylene Blue API often meets pharmacopoeial standards but may not require GMP certification. Suppliers like LGC Standards cater specifically to research applications.

3. What regions are considered most reliable for bulk Methylene Blue API procurement?
Europe, North America, and India generally offer reliable sources with standard adherence; China also provides competitive options, though due diligence on quality certifications is advised.

4. How do regulatory differences impact API sourcing?
Manufacturing and API standards must comply with the importing country’s regulations. For instance, APIs for human use require GMP compliance, while research applications may have more lenient standards.

5. What logistical considerations should be accounted for when ordering Methylene Blue API in bulk?
Lead times, packaging integrity, transportation conditions (light protection), customs clearance, and import licenses are crucial factors influencing timely delivery and quality preservation.


References

[1] United States Pharmacopeia (USP). Methylene Blue Monograph.
[2] European Pharmacopoeia (EP). Methylene Blue Specifications.
[3] Sigma-Aldrich Product Page. Methylene Blue API.
[4] Biosynth Carbosynth. High-purity Methylene Blue.
[5] Indian Pharmaceutical Directory 2023. API Manufacturers List.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.